We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and ...

Altimmune Inc. ALT shares rallied more than 40% in the extended session Thursday after the clinical-stage biopharma company said 391 people enrolled in a trial of its obesity drug pemvidutide lost ...

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 ...

Altimmune, Inc. is a Gaithersburg, Maryland based clinical-stage biotechnology concern focused on the development of therapies for obesity and liver disease. After the recent (March 2024 ...

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company focused on ...

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's ...